- A team of biotech heavyweights have developed a bio-chemistry platform that rapidly and accurately identifies a wide range of pathogens and infectious diseases, as well as a host of other medical conditions.
- This amounts to a democratic upheaval in the $93 billion diagnostic testing market … Gemina Lab’s tests are faster, better, and ready to use at point of care… no lab visits needed.
- Within weeks, the company will begin rollout of an at-home Covid test so accurate that it surpasses the most trusted tests on the market: 5X more sensitive than Abbott or ID Now, and 11X more sensitive than Rapigen.
- Just following successful completion of human trials for their rapid Covid Antigen test, the company has secured a highly sought after EU CE Mark, which will accelerate commercialization throughout the EU.
- By year-end the company’s Multiplex Respiratory panel will mark a testing breakthrough with global health potential. The test will allow for rapid diagnosis of 11 contagious virus or bacterial infections that affect millions every year, such as strep, staph, or adenovirus.
- This is gold standard patient care that doctors should embrace quickly and savvy investors should immediately consider.
An under $1 microcap is quietly cornering one of the world’s largest healthcare markets: point-of-care diagnostics.
It’s a market that’s expected to hit $93.211 billion by 2030 at a remarkable 11.1% CAGR.
With a current value of about $41.49 billion, that’s an incredible amount of growth in a short time. Yet so far, the market has been dominated by giants, like Roche, Abbott, and Bayer.
That’s about to change as a few small but innovative companies ride the sector’s rocket-speed growth.
If you’re wondering how a tiny company could shake up an industry of titans… it actually happens all the time.
Just take a look at a handful of startups who saw their valuations soar after bringing unique biochemical solutions to the market.
- Gemina Lab’s own CEO, John Davies, previously helped found Oxford Nanopore. The stock for that DNA sequencing company is now worth $4.1 billion2.
- Cue Health, which makes portable diagnostic tests, listed its stock in September 2021 and hit a $1.96 billion market cap by year end.
- Foundation Medicine invented a genome profiling system for personalized cancer treatment. It began as a tiny operation, running its first tests in 2012. Six years later, Roche bought it for $6.7 billion.
And now, Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) is within weeks of launching its first product.
That has the makings for a knock-it-out-of-the-park opportunisty for investors who know how explosive medical technology companies can be, especially when they bring the level of versatility Gemina’s products offer.
It also signals a key turning point for investors: Gemina is that much closer to proving it can generate revenues from operations. That’s the lifeblood of success. And this moment, right before first sales, could be the last chance to get in early.
A $93 billion market in dire need of an overhaul
Sometimes a company so obviously answers a need that nobody can doubt its importance.
Over the last decade, consumers have been subjected to an increasingly impersonal and dysfunctional healthcare infrastructure.
Doctor appointments that take weeks to book… specialist visits that take insurance months to approve… tests that take days to deliver results… and then there are the rising costs for standard medical tests and procedures.
It has begun to wear thin on the public.
In the last few years especially, it’s become increasingly clear that patients need access to affordable, laboratory quality tests that can be conducted at home – where results can be acted upon immediately.
That is exactly what Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) has accomplished through the development of an innovative biosensor technology. Their ‘first-of-its-kind’ diagnostic testing platform has enormous global potential.
The best part is, they’re opening up access to hundreds of applications across a wide range of health issues, in areas such as cardiac health, inflammation, pathogen, viral, or bacterial infections… even cancer.
The company is also exploring opportunities to adapt their technology to assess stress and anxiety levels, measure nutritional deficits, and monitor exercise performance and recovery testing, offering them access to a consistent multi-trillion athletic industry.
And they couldn’t have chosen a better time to launch their first suite of products, as a massive shift towards personalized healthcare gains favor with the public.
Adaptable point-of-care testing, for a fast-changing world
When engineering the platform, Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) had two key objectives in mind.
First, they wanted their product to perform better than existing tests, increasing the possibility of early detection, and avoiding the devastating effect of false positives.
Second, the company wanted to create simple but robust technical foundation that allowed for endless adaptability. This would allow the company to continue pursuing opportunities for new tests, while also simplifying the manufacturing process, resulting in reduced production costs. And in turn, reduced costs to the consumer.
Over the course of seven generations of development, Gemina has delivered a unique chemical platform with a flexible approach to addressing the target, be it a virus, antibody, small molecule or even DNA.
To put it in the simplest terms, the chemistry on one end of the sensor has an affinity with the surface that is to be tested for whatever the current target is, whether pathogen, or other type of molecule.
At the other end of this chemical chain, the sensor traps that target… but only specific ones. Those trapped molecules are what allows the device to confirm whether a virus, bacteria or pathogen is present or not.
Results can then go straight to Testpoint, Gemina’s digital smartphone application, where it can be digitally integrated into healthcare and insurance providers data systems.
As they continue to develop the technology, the company intends to take it even a step farther. The company is also hoping to provide a “how much” measure of concentration, that enables the daily monitoring of chronic conditions.
Proprietary chemistry platform allows for dramatically improved accuracy
While the company’s technology is purpose-built to serve many mediacal needs, the first test that will hit the market will be for SARS CoV2.The Gemina Legio X Rapid Antigen test completed human trials in late spring, and now has been awarded the coveted EU CE Mark, which signifies that the product meets the EU’s stringent safety, health, and environmental protection requirements
Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) is currently continuing to advance this initial test through manufacturing feasibility studies and has just received the phase 1 final report. Gemina’s is currently pursuing licensing arrangements for the COVID-19 test with an established manufacturer.
What that means for investors is…
- The concept is proven.
- The manufacturing is ready to roll.
- And the distribution plans are in the works.
The best part, Gemina’s test is faster, cheaper, and more sensitive than the industry staples that are currently in widescale use…
As much as 11X more sensitive
In April 2021, The Lancet, one of world’s oldest and best-known general medical journals, published a comparison of seven Covid tests available last year.
Then, just a few months later, Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) came along and beat them all.
A more sensitive test can detect infections that are just in their beginning stages, sometimes before symptoms even appear. That means a diagnosis can be made early enough for treatment before things get serious or before medically vulnerable individuals have been exposed.
It also means that false positives won’t happen as often, an increasingly devastating obstacle, with as many of 5% of positive cases turning out to be false readings3. In turn, false positives contribute to lost wages, and staffing issues that amount to decreased business revenues and supply chain disruptions.
Critical solutions for a global market
The rapid Co V2 test is just one of many milestones the company has targeted for the near term.
Within a year, Gemina will also be rolling out a multiplex respiratory panel that offers instant results – identifying strep, staph, adenovirus, or any of 11 other contagious virus or bacterial infections that need treatment.
Tens of millions of people are affected by respiratory diseases, each year. Even in the US, Canada, and advanced countries, humans develop strep infections that can lead to joint infections, rheumatic fever, kidney inflammation, and even heart valve damage. The World Health Organization estimates that every year, 4 million people a year die from respiratory diseases4.
Gemina Labs’ (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) respiratory panel offers a much needed, and markedly superior solution to this growing need.
- They’re faster. 20 minutes for a respiratory panel, 4 minutes for a Covid test, versus a full day or more for in-lab tests that must wait for cultures to grow.
- They’re financially attractive. A lab-run respiratory panel costs $150 to $200 for the basic version at the minimum. That’s compared to around $20 for Gemina’s at-home test.
- They’re healthier. In a world with rampant bacterial and viral pollutants, hospital and medical lab test waiting rooms are a hot zone for germs. Anything that keeps sick people away from other sick people is a positive.
- They’re more sensitive. Gemina’s Covid test detects levels that at 5X to 11X smaller than the best detection levels other companies’ tests can achieve.
- They’re more informative. Yes/no answers aren’t always enough. GLAB is developing tests that will indicate a “how much” level of concentration is present. This will allow monitoring and watching progress to guide better treatment.
Then there’s the wellness market, a $4 trillion behemothh in its own rite.
Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) is fast at work there too, with a suite of products that will help customers better understand their body’s chemistry, so they can make informed adjustments that allow them to exercise, eat, and sleep better.
That means individuals can quickly discover issues that are holding them back from optimal health, such as high cortisone levels or an amino acid deficit.
Gemina anticipates the completion of its prototypes within weeks, allowing them to launch their initial two wellness products potentially within a matter of months.
Late 2022: Athletic biomarkers panel WT1
This panel can evaluate things like nutrition, hydration, endurance factors, indicators of muscle damage and muscle potential, and factors that govern risk such as bone minerals.
Very Early 2023: Stress and anxiety prototype WT2
This panel focuses on stress indicators like cortisone and amino acids that occur in excess quantities with chronic stress.
Those tests are already well along, but the same technology has enormous future potential. A few things we can expect as Gemina runs through its pipeline:
Micronutrient testing—problems like fatigue, anxiety, weight gain or loss, and digestion can result from a deficit of important micronutrients. This testing allows users to choose exactly what vitamin and mineral supplement will help and avoid a shotgun approach that can oversupply the wrong ones.
Metabolism questions—measuring hormones that affect your body shape and weight include thyroid stimulating hormone, as well as testosterone and cortisol levels.
Heart health—various measures that indicate cardiac risks and current conditions such as low vitamins, cellular hemoglobin, liver and kidney function, electrolytes and more.
As you can see, the application possibilities are endless, and Gemina has made it clear their intentions are too.
One of the largest patent portfolios we’ve seen
Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF) has filed a provisional patent that includes 226 claims relating to its surface chemistry platform for biosensing applications. This patent filing also covers eight related families of chemistry based on CEO John Davies’ and CTO Rob Greene’s research, along with the work of the Gemina scientific Research and Development team. Davies is rightly proud:
“I’ve had the pleasure of finding and commercializing technologies based on proprietary IP for more than 25 years, often created within labs at some of the leading institutions of the world …not only do I believe that Gemina’s IP is amongst the most exciting I’ve ever had the opportunity to work with, but I can say without hesitation that this filing is the most comprehensive and vast compilation of unique intellectual property that I have had the pleasure of being associated with.”
A CEO and scientific advisory team like no other
The company is led by John Davies, who has over twenty years of successful experience in R&D commercialization. As a member of the founding team at London Stock Exchange listed IP Group, he created the foundations for a company now worth over $2 billion. In his role at IP Group, John helped commercialize more than 65 technologies, including Oxford Nanopore.
John Davies crafted Gemina’s strategy using the same approach that proved successful with companies such as Oxford Nanopore – combining breakthrough chemistry with proprietary technology to deliver fast and effective diagnostic outcomes at the point of need.
Head of Productization, David Browning has 40-year track record that includes work at Amersham, J&J, IGEN and Roche.
Chief Technology Officer, Rob Greene, has provided the key work, alongside Davies, that is the basis for Gemina’s patentable intellectual properties.
Then there’s a bona-fide biosensor star. That’s Chief Advisor Mike Catt. He’s a full professor and Turing Fellow at Newcastle University who spent his diagnostic career working on products at Swiss Precision and Unilever.
Catt has published dozens of research studies in high-prestige journals and is the kind of scientist that other scientists often cite.
He was on the team that pioneering the Clearblue lateral flow assay pregnancy test, the world’s first rapid, one-step test.
He’s also worked on tools and interventions for healthy aging at Unilever. At Newcastle he has taken up reins as the Director of the university’s National Innovation Centre for Ageing. And we expect he’ll help Gemina tap into the huge needs for senior wellness.
- Gemina Labs has a low-cost edge. Traditional in-lab testing costs hundreds of dollars. A biosensor point-of-care test like Gemina’s costs $20 or less. With equal accuracy and much faster results. It’s an easy sell.
- The potential is almost infinite. The reason to invest in Gemina is more than its current Covid test, or its respiratory panel, or even its soon-to-launch wellness tests. The technology behind every one of those is the same and Gemina owns it. Moreover, it can be used to create tests for gastrointestinal diagnoses, blood chemistry, vaginal infections, central nervous system chemistry, even specialized panels for hard to diagnose syndromes.
- More ways to hit the jackpot. At the moment, Gemina Labs is a full steam ahead, functioning business from research to product development to actual manufacture. That makes it particularly attractive to big-tech companies interesting in buying it out.
- Licensing multiplies its reach. Gemina has the brain trust. It can now use its intellectual property to develop multiple tests. And it can license its work to any number of companies to keep the revenues flowing.
- Superior leadership. The team at GLAB is experienced and successful at turning bright new technologies into solid business successes.
Gemina’s first tests will reach the market very soon. Once word gets out, even more, the demand for this disruptive new technology will likely be intense – and all bets are off for shares in Gemina Labs (CSE:GLAB, OTC:GLABFCSE:GLAB, OTC:GLABF)
We see years and years of climbing revenues and a whole pipelines of tests emerging.
Talk to your broker. The time to investigate this company is now, before product sales begin for this breakthrough biotech technology that could potentially benefit the lives of millions across the globe.
1https://www.globenewswire.com/news-release/2022/01/07/2363168/0/en/Point-of-Care-Diagnostics-Market-Size-to-Hit-USD-93-21-Bn-by-2030.html
2https://finance.yahoo.com/quote/ONT.L/ quote Ap 6, 2022
3https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850182/
4https://www.vitalstrategies.org/four-million-deaths-each-year-caused-by-acute-respiratory-infections-new-at/
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Gemina Labs (“GLAB”) and its securities, GLAB has provided the Publisher with a budget of approximately $50,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by GLAB ) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of any profiled company GLAB and has no information concerning share ownership by others of in the profiled company GLAB . The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to GLAB industry; (b) market opportunity; (c) GLAB business plans and strategies; (d) services that GLAB intends to offer; (e) GLAB milestone projections and targets; (f) GLAB expectations regarding receipt of approval for regulatory applications; (g) GLAB intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) GLAB expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute GLAB business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) GLAB ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) GLAB ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) GLAB ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GLAB to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) GLAB operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact GLAB business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing GLAB business operations (e) GLAB may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
- The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Gemina Labs.
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled Gemina Labs and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Gemina Labs or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Gemina Labs. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Gemina Labs’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Gemina Labs future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Gemina Labs industry; (b) market opportunity; (c) Gemina Labs business plans and strategies; (d) services that Gemina Labs intends to offer; (e) Gemina Labs milestone projections and targets; (f) Gemina Labs expectations regarding receipt of approval for regulatory applications; (g) Gemina Labs intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Gemina Labs expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Gemina Labs business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Gemina Labs ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Gemina Labs ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Gemina Labs ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Gemina Labs to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Gemina Labs operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Gemina Labs business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Gemina Labs business operations (e) Gemina Labs may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Gemina Labs or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Gemina Labs or such entities and are not necessarily indicative of future performance of Gemina Labs or such entities.
